Effect of Febrile Neutropenia Guideline’s Implementation on Death Rate in Dharmais Cancer Center Hospital

Dody Ranuhardy


ABSTRACT Febrile neutropenia may have a high morbidity and mortality impact for the patient. The death rate of febrile neutropenia in 2002 was 38.8%, while in 2009 was 27.3%. The difference in mortality rates could caused by several factors such as availability of the Neutropenic Fever Management Guidelines in 2006, in addition to infrastructure, human resources and equipment. This study aims to determine the effect of the availability of the guideline and other factors to cancer mortality rate in the compromised immune isolation room of Dharmais Hospital. This study is a cross-sectional retrospective study which investigate mortality rates and compare with adherence to febrile neutropenia guidelines for the period 2008-2012. Data were taken from the patient's medical record file, then analyzed using univariate and bivariate analysis. The mortality rate in the period 2008-2012 was 20,7%. The effect of age, sex, and degree of risk factor on mortality was not significantly different (p=0,409, p=0,404, and p=0,324). The proportion of deaths was higher in patients borne by third parties (26.8%) than in the case of personal (10%) although not statistically significant (p=0,065). Of the three types of adherence, only one had a significant effect of adherence to treatment flow (p=0,033).


guidelines of febrile neutropenia; compromised immune isolation room; mortality rate

Full Text:



Naurois J, Basso N, Gill MJ, et al. Management of Febrile Neutropenia: ESMO Clinical Clinical Practice Guideline. Annals of Oncology. 2010; 21(5): 252-6.

Thursky KA, Worth LJ. Can mortality of cancer patients with fever and neutropenia be improved?. Wolters Kluwer Health, Inc. 2015; 28(6): 505-13.

Kyriacou DN, Jovanovic B, Frankfurt O. Timing of initial antibiotic treatment for febrile neutropenia in the emergency department the need for evidence-based guidelines. JNCCN. 2014; 12(11): 1569-73.

Penack O, Buchheidt D, Christopeit M, et al. Management of sepsis in neutropenic patients: guidelines form the infections disease working party of the German Society of Hematology and Medical Oncology (AGIHO). Ann Hematol. 2014; 93: 1083-95.

Ranuhardy D. Panduan Tata Laksana Febril Neutropenia/Demam Neutropeni pada Pasien Kanker. Jakarta: Balai Penerbit FKUI; 2006.

Ranuhardy D, Sandy D. Febrile Neutropeni pada Pasien Kanker di Rumah Sakit Kanker Dharmais, Evaluasi Keadaan Tahun 2009 (Studi Retropektif). (Unpublished); 2009.

Lustberg MB. Management of neutropenia in cancer patients. Clinical Advance in Hematology Oncology 2012;10(12):825–6.

Djasri, Hanevi. Pemilihan dan Penerapan Pedoman Klinis (Clinical Practice Guideline). Yogyakarta: Bahan Kuliah Audit Klinik MMR; 2011.

Kern, Wifried V. Current Epidemiology of Infections in Neutropenic Cancer Patients. In Textbook of Febrile Neutropenia. Kennet VT Rolston, Edward B. Rubenstein (Eds). UK: Martin Dunitz Ltd; 2001. p 57-8.

Lyman GH, Rolston KV. How we treat febrile neutropenia in patients receiving cancer chemotherapy. J Oncol Pract. 2010; 6: 149–52.

Meisenberg B, Clemons J, Ness J, et al. Improving hospital performance in the treatment of febrile neutropenia. Support Care Cancer. 2015; 23: 371-5.

DOI: http://dx.doi.org/10.7454/arsi.v4i3.2551


  • There are currently no refbacks.